Please assess the completion status of the following clinical trial:

Trial Title: First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Patient with histologically-confirmed, locally advanced or metastatic tumor who has progressed on standard therapy or for whom no standard therapy exists, with the following restriction:~   * Part I: solid tumors of any origin;~  * Part II: breast, gastric, urothelial and endometrial tumors;~2. For Part II: HER2 tumor status as defined in the protocol;~3. ECOG performance status ≤ 1;~4. Life expectancy \> 12 weeks;~5. Adequate organ function;~6. For Part II: measurable disease.~Main Exclusion Criteria:~1. Anthracycline treatment within 3 months and/or abnormal cardiac biomarker values;~2. Other anticancer therapy (except for LHRH agonists) within 4 weeks (6 weeks for nitrosoureas and mitomycin C);~3. History of infusion-related reactions and/or hypersensitivity to trastuzumab or (ado-) trastuzumab emtansine;~4. Severe, uncontrolled systemic disease;~5. LVEF \< 55%, or a history of absolute decrease in LVEF of ≥ 10% points to \< 50% during previous treatment with trastuzumab or (ado-)trastuzumab emtansine, or a history of decrease in LVEF to \< 40% during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;~6. History of clinically significant CV disease;~7. Symptomatic brain metastasis, or therapy for brain metastasis (excluding PCI and dexamethasone treatment with stable or decreasing daily dose) within 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYD985 (trastuzumab vc-seco-DUBA) (Type: EXPERIMENTAL): HER2-targeting Antibody-Drug Conjugate

Based on this trial design, predict the completion outcome and termination type (if applicable).